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Abstract. Preterm birth constitutes a major cause of death before 5 years of age and it is a major cause of
neurodevelopmental impairment across the world. Preterm infants are most unstable during the transition
between fetal and newborn life during the first days of life and most brain damage occurs in this period.
The brain of the preterm infant is accessible for tissue oximetry by near-infrared spectroscopy. Cerebral oximetry
has the potential to improve the long-term outcome by helping to tailor the support of respiration and circulation to
the individual infant’s needs, but the evidence is still lacking. The goals for research include testing the benefit
and harms of cerebral oximetry in large-scale randomized trials, improved definition of the hypoxic threshold,
better understanding the effects of intensive care on cerebral oxygenation, as well as improved precision of
oximeters and calibration among devices or standardization of values in the hypoxic range. These goals
can be pursued in parallel. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution
or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.NPh.3.3.031407]
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1 Introduction
1.1 First Studies in Preterm Infants
Near-infrared spectroscopy (NIRS) was first applied to preterm
infants 30 years ago by Brazy et al.1 and demonstrated mean-
ingful correlations between apnea and arterial pO2 on one side
and cerebral oxyhemoglobin and oxidized cytochrome aa3 con-
centrations measured by NIRS on the other side. The following
year, a correlation between PaCO2 and cerebral blood volume
and cerebral oxygenation index measured by NIRS was
demonstrated2 and 5 years later we could publish statistically
strong correlations between cerebral blood flow measured by
xenon clearance and cerebral blood volume and cytochrome
aa3 oxidation as estimated by NIRS.
3
Thus from the first applications, the preterm brain appeared
perfectly suited for monitoring by NIRS, covered only by thin
layers of skin, scalp, skull, and cerebrospinal fluid, and the word
“promising” was used repeatedly in the literature that followed.
A search on PubMed using the terms “NIRS or near-infrared”
and “newborn or preterm” now yields 982 entries. While the
hemoglobin oxygenation signal has achieved a high degree of
construct validity, this is still being worked out for the cyto-
chrome aa3 signal.
4
1.2 Problem of Quantification
The cerebral hemoglobin signals have been used to study a large
variety of clinical questions. In this they have rarely produced
surprises, i.e., cerebral oxygenation and blood volume have
changed in the direction expected, but unfortunately, the abso-
lute values have often been inconsistent. As an example, using
the data from the two publications quoted above reporting a
relation between PaCO2 and cerebral blood volume, widely dif-
ferent values are obtained (0.5 to 1.9 versus 0.07 mL per kPa).
Nearly 100 reviews have been written on NIRS and the pre-
term brain to date. The focus of the present review is the poten-
tial for clinical use to improve the outcome of preterm infants,
and thus builds on and expands a previous article.5
We here describe a research agenda with three components:
randomized clinical trials to test the clinical value, pathophysio-
logic studies to quantify the effectiveness of clinical interven-
tions, and improved instrumentation. We will argue that these
research fields should be explored in parallel, rather than in
the logical sequence: instrumentation, effectiveness, and clinical
benefit. The reason is that there is a risk that cerebral oximetry—
as many other diagnostic methods—will enter clinical routine
without good evidence of clinical benefit, i.e., there is a window
of opportunity, which must be used.
2 Clinical Problem
Prematurity is now the leading cause of death of children under
5 years of age worldwide.6 In Europe alone, 25,000 infants are
born every year with a gestational age of less than 28 weeks, of
which 5000 die.
Preterm infants often require intensive care to support their
immature respiratory and cardiovascular system. This may be
during the first few days of life when the transition from
fetal to neonatal life takes place or during complications later
in the neonatal period such as episodes of sepsis or necrotizing
enterocolitis. Infants needing intensive care have higher risk of
neurodevelopmental impairment. This fact suggests that there is
room for better tailoring of this intensive care to the needs of the
individual infant, e.g., by improved monitoring.
2.1 Need for Improved Clinical Monitoring
A particular problem is to strike the balance between too little
and too much oxygen. After five large randomized controlled*Address all correspondence to: Gorm Greisen, E-mail: greisen@rh.dk
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trials comparing target ranges for pulse oximetry of 86% to 89%
and 91% to 95%, it is still uncertain which is better.7 The likely
reason for this is that arterial oxygen saturation as monitored by
pulse oximetry is only one of the factors of significance for tis-
sue oxygen sufficiency and the risk of tissue hypoxia. The other
major factors are blood hemoglobin concentration and tissue
blood flow on the delivery side and tissue oxygen consumption
on the uptake side. While hemoglobin concentration is easily
available in clinical routine, blood flow and oxygen consump-
tion are not. This is why tissue oximetry is relevant as a direct
measure of oxygen sufficiency.
The tissue oxygenation (StO2) is the oxygen-hemoglobin
saturation in the blood inside the blood vessels in that tissue.
In case of hemorrhage, extravascular blood is also included.
It can be measured by NIRS using a range of different methods,
the description of which is outside the scope of this review.
2.2 Case for Cerebral Oximetry
The brain of the preterm infant is particularly vulnerable.
Although modern neonatology has significantly improved the
chances of survival, the risk of neurodevelopmental impairment
remains high. As an example, the risk of cerebral palsy is 1 of
1000 in term born infants, 1 of 100 at 34 weeks gestation, and
1 of 10 at 26 weeks gestation, and in Europe alone 5000 infants
with gestational age below 28 weeks survive with neurodevelop-
mental deficit after brain injury each year.
The most common forms of brain injury in preterm infants
are diffuse8 and hypoxia-ischemia, as well as peroxidation
operates in concert with a range of other etiologic factors.
Oxygenation of different regions of the brain does not appear
to differ in preterm infants.9 This means that simple one-channel
monitoring of the oxygenation of any region of the brain is
likely to provide information that has the potential to benefit
the infant by tailoring the intensive care, i.e., by modifying
ventilatory or circulatory support (Fig. 1).
2.3 Current Status
The SafeBoosC-II trial showed that it is indeed possible to
reduce the burden of cerebral hypoxia in extremely preterm
infants during the first 3 days of life when adding cerebral
oximetry to the already complex standard care.10 The burden
was quantified as “the area under the curve” when the cerebral
oxygenation was below a threshold of 55%. The reduction was
achieved by the use of continuous open-screen monitoring of
cerebral oxygenation combined with a physiology-based treat-
ment guideline suggesting how to intervene when the cerebral
oximeter showed values outside the target range (Fig. 2).11
Perhaps surprisingly, many oximeter alarms were ignored,
and most interventions only involved adjusting the fraction of
inspired oxygen, i.e., using the cerebral oxygenation measure
much like the reading from a pulse oximeter. But significant
numbers of adjustments of the ventilatory and circulatory sup-
port were also recorded.12
The burden of cerebral hyperoxia was small and not influ-
enced by interventions.
A similarly designed randomized clinical trial tested the
value of monitoring of cerebral oxygenation in the delivery
room during the first 15 min of life in preterm infants. Also
in this trial the burden of cerebral hypoxia—as defined by a
minute-to-minute reference curve—was reduced in the NIRS-
visible group.13
2.4 What Is to Be Done?
The SafeBoosC trial discussed above involved 166 extremely
preterm infants in eight university centers in Europe and was
not powered to demonstrate an effect on clinically relevant out-
comes such as brain injury, other complications, or survival, and
did not do so.10,14,15 Similarly, the trial in the delivery room
involved only 60 preterm infants and also did not demonstrate
a clinical benefit. The problem is that while cerebral oximetry
certainly has the potential for clinical benefit, it also has poten-
tial for harm. First, the sensors may injure the skin by heat and
pressure. Second, adding another sensor and another cord to the
already crowded and complex intensive care situation may con-
fuse and take caregiver time from more important aspects of
care, and use economic resources that could be spent better.
Third, interventions that aim to improve cerebral oxygenation
may have side effects.
A new, larger phase-III randomized trial is thus needed.
A traditional RCT involving 1600 extremely preterm infants
would have the power to detect a reduction in the risk of severe
Fig. 1 The ultimate goal is to support preterm infants in an individu-
alized manner during the physiological transition from fetal life. Due to
their size and fragility all measures must be carefully adapted to their
needs. Cerebral oximetry by NIRS has the potential to detect harmful
cerebral hypoxia for timely intervention.
Bu
rd
en
 o
f h
yp
ox
ia
 (%
ho
urs
)
0
20
0
40
0
60
0
80
0
Experimental Control
Fig. 2 The burden of cerebral hypoxia in 166 extremely preterm
infants included in the SafeBoosC-II randomized clinical trial. The bur-
den was reduced to less than half in the experimental group. The con-
trol group had blinded recording of cerebral oxygenation while the
experimental group had the actual cerebral oxygen displayed and
could act on cerebral hypoxia with the help of a clinical guideline.
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brain injury or death at 36 weeks of postmenstrual age from
34% to 27%. Funding for such a trial was applied for by the
SafeBoosC consortium in the EU Horizon2020 program, but
unsuccessfully.
This leaves three likely scenarios. First, a large, pragmatic
trial, perhaps cluster randomized, is realized to address the bal-
ance between benefit and harm in an effective way. Second, sev-
eral smaller trials with similar interventions and outcomes are
combined in a meta-analysis. Either way funding would parti-
ally have to be found locally. Third, as it is most common for
new diagnostic and monitoring methods, cerebral oximetry will
gradually enter clinical routine as driven by local professional
ambition and marketing pressure without real evidence of ben-
efit for patients and value for money for health providers. As
examples, neither pulse oximetry nor transcutaneous monitoring
of pCO2 has been evaluated in a stringent way in newborn
infants. While pulse oximeters are in general use, this is not
the case for transcutaneous monitoring of blood gases. More
generally, new diagnostic methods may, apart from their own
side effects and costs, potentially cause overdiagnosis and over-
treatment. Currently, efforts are made to reduce what is per-
ceived as unnecessary monitoring with pulse oximetry.16
It is a key problem that funding of formal testing of clinical
benefit is not economically feasible for the industry and not
required for approval of medical devices for clinical use.
3 Clinical Research Problem
Apart from the large-scale testing of the overall clinical benefit
of monitoring of the cerebral oxygenation during intensive care,
the value of individual interventions could be much better doc-
umented. While the ultimate goal is maximizing the chance of
survival with a normal brain, improved knowledge of the path-
ophysiology that drives the poor outcomes is important for
rational interventions.
3.1 Better Definition of the Target Range for
Cerebral Oxygenation
For oxygenation really to enter everyday intensive care as a
monitor, it has to come with a display of the current value,
the trend, and a visible and audible alarm. But to set the alarm,
it is necessary to know the safe range.
The first problem in setting a safe range is that cerebral oxy-
genation is a poorly defined physiological quantity. The best
description is a venous-weighted tissue hemoglobin-oxygen
saturation, indicating that the proportion of venous to arterial
blood in the signal is uncertain and possibly varying. As the
value appearing on the cerebral oximeter also represents a
poorly defined lump of tissue, it is unreasonable to expect a
close quantitative relation to other, better-defined physiological
measures. Therefore, true validation is not possible, and any
target range must be defined by construct validity.
3.2 Population-Based Reference Ranges
Recently, reference ranges for the first 3 days of life in preterm
infants divided into gestational age bands were published.17 For
gestational age 24 to 27 weeks, the 10th centile was around 55%
using the INVOS device with the adult sensor. These reference
ranges were based on a very large number of infants. Differences
were detected depending on the day after birth, gestational
age by week, sex, and whether the infant was normally grown
or small for gestational age. Although the differences were small
to moderate of size, their statistical significance was great due
to the large number of infants involved.
Unfortunately, reference ranges do not define optimality. The
reference range for cerebral oxygenation is lower for infants
with gestational age 24 to 25 weeks compared to infants
with gestational age 30 to 31 weeks, but their risk of brain injury
is also higher, and does the lower cerebral oxygenation play
a role in this?
3.3 Experimentally Based Hypoxic Thresholds
In the newborn pig, experimental evidence shows that a thresh-
old of 55% includes a safety margin to allow almost all animals
to maintain normal cerebral lactate and ATP,18 while it takes
30 min at a cerebral oxygenation of 35% to cause mitochondrial
damage19 and more than 2 h to cause neuronal death.20 As the
pig brain is relatively mature at birth, this work should be
repeated in animal models with brain maturation corresponding
to extremely preterm infants and explore the effects of repetitive
hypoxic insults, and the use of markers of milder damage and of
damage to white matter.
3.4 Safe Ranges Based on Association with
Brain Injury
Linking cerebral oxygenation to brain injury diagnosed in the
neonatal period or neurodevelopmental impairment at follow-
up has been attempted in several studies. “Fluctations” in
cerebral oxygenation is associated with brain hemorrhage.21
Perhaps more significantly, lower levels of cerebral oxygenation
have been associated with poor brain outcomes.22–26 Future
work should use a predefined strategy for data analysis, e.g.,
drawing a receiver-operating curve for the prediction of severe
brain injury for varying levels of cerebral hypoxic burden. This
could help the construction of the rationale for one rather than
another threshold for intervention. Also, future work should
focus on timing. For cerebral hypoxia to cause brain injury
it has to precede—not follow—the injury. It is a further
complication that after a serious hypoxic-ischemic insult
a phase of cerebral hyperperfusion and hyperoxygenation
follows27 and it is a challenge to sort this out in the statistical
analysis.
3.5 Improved Rationale for Clinical Responses to
Cerebral Hypoxia
When cerebral oximetry is used clinically, the effect of an inter-
vention to bring back cerebral oxygenation into the target range
can be observed directly, and hence provide better evidence of
effectiveness in that particular situation in that particular patient
than any piece of research on a group of similar patients. This is
the power of a clinical monitoring tool, as it allows real individu-
alization of care.
For the choice of intervention in the first place, however,
good understanding of physiology and pathophysiology is use-
ful. While reducing mechanical ventilation in an infant with a
slightly low pCO2 and cerebral hypoxia is uncontroversial, the
use of a vasopressor in an infant with a slightly low arterial
blood pressure and cerebral hypoxia is not. Two current trials
address this issue.28,29 Similarly, a large project addresses the
usefulness of inotropic drugs to support the immature heart,30
also in terms of cerebral oxygenation.
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3.6 Difficult Case of Erythrocyte Transfusion
Most interestingly, several studies have demonstrated increased
cerebral oxygenation after blood transfusion in preterm infants,
most recently in infants during the first day of life and occurring
only in infants with a low pretransfusion cerebral oxygenation.31
The effects of blood transfusion are complex, involving
blood oxygen-carrying capacity and blood viscosity on one
side and venous pressure and filling of the heart on the other.
In situations with sufficient oxygen delivery to the brain, trans-
fusion will simply lead to cerebral vasoconstriction through
metabolic regulation. In one study, the effects of transfusion
on cerebral oxygenation as well as on brain blood flow by
Doppler were measured.32 By combining oxygenation and
blood flow data, transfusion appears to reduce brain oxygen
consumption—a highly unlikely event.
So it is not entirely clear if the increased cerebral oxygena-
tion measured after transfusion really represent an increased
delivery-to-consumption balance. Other possible explanations
could be a shift in the oxygen-hemoglobin dissociation, or
a shift in the venous to arterial blood volume ratio. Future
studies should include measures of cerebral blood flow and
cardiac output to disentangle the mechanisms to pave the way
for an individualized use of blood transfusions.
3.7 More Intelligent Use of Information on
Cerebral Oxygenation
The clinical trial of benefit and harm as described above will use
cerebral oxygenation as a simple variable: an alarm will sound
at a preset threshold and call for intervention. But even if this
simple approach fails to deliver clinical benefit, it is possible that
a more advanced approach could be useful, e.g., by combining
absolute levels, trends, past reactions to intervention, and other
clinical data.
4 Technical Problem
4.1 Precision
Lack of precision is the first problem. Precision is the ability to
reach the same result repeatedly, and thus is the basis of “repro-
ducibility.” In clinical practice, single values inform treatment
decisions, whereas statistically significant results in research
come from averages, and where imprecision is just one of
many sources of variance.
The first study focusing on the precision of cerebral oximetry
reported a standard deviation of measurement of 5.2% after
repeated replacement of the probe on the head of stable preterm
infants.33 This level of (im)precision has been confirmed by
others. The precision after replacement on a solid homogenous
phantom is typically less than 1%, and the typical spontaneous
variability over time in stable preterm infants is typically less
than 2%.
As there is little evidence to support the idea of significant
variability of oxygenation in different brain regions,9 the most
likely explanation for this stubborn imprecision is the optic
heterogeneity of the preterm head. To address this problem, a
spatially resolved device was developed that combined a self-
calibrating algorithm and simultaneous measurement from two
adjacent regions. Four light-emitting diodes and two photodio-
des were put in a hexagonal arrangement. Unexpectedly, this
device did not produce better precision, possibly due to light
piping as a result of imperfect contact with the relatively hard
newborn head.34
A precision standard deviation of 5% corresponds to a
repeatability coefficient of 14%. This means that the value
from a probe that has been moved, or is sitting on another infant,
has to differ by more than 14% in order to be taken to indicate
that cerebral oxygenation really differs with a certainty of
95%. Fourteen percent is a great deal considering that the typical
value is around 70% and the threshold for intervention is
around 55%.
It has therefore been proposed to rely on trends only for clini-
cal use, i.e., to disregard the absolute value, most radically by the
use of a zero-setting procedure. This is a way of circumventing
the lack of precision, the lack of accuracy, as well as the uncer-
tainty of the hypoxic threshold. Whereas this may be meaningful
in awake patients before anesthesia for heart surgery, it is not
for preterm infants during the transition from intrauterine to
extrauterine life since there is no initial normal state. Also,
replacement of the probe or movement during prolonged mon-
itoring may result in the same precision problem.
4.2 What Is to Be Done?
Technical development to improve the replacement precision is
welcome. Perhaps other technologies than spatially resolved
spectroscopy may prove better. A reasonable goal would be a
precision in the same order of magnitude as the spontaneous
variability over time in stable patients, i.e., 2% to 3%.
4.3 Agreement
Cerebral oxygenation is an ill-defined physiologic quantity and
therefore true validation is not possible. What has been done is
calibration to oxygenation of blood drawn from an artery and a
“cerebral” vein, usually the jugular vein in humans and some-
times the superior sagittal sinus in experimental animals. First,
this depends on the assumption of a rather arbitrary arterial-to-
venous ratio; second, the venous sampling sites are not ideal
compared to the tissue actually measured. While it is obvious
that cerebral oxygen saturation cannot exceed arterial saturation,
it may actually be lower than venous saturation in situations with
significant cerebral flow-metabolism heterogeneity.35
A more modest goal is agreement between different devices.
The problem is that different devices that are approved for
clinical use give different values.
Is has been consistently shown that the sensors for neonatal/
pediatric use give ∼10% points higher readings as compared to
sensors for adult use with the same device.36–38 While it may
be appropriate to calibrate a probe for a specific patient
group or even a specific organ of interest, it is not entirely
clear how this calibration was made or if the result is closer
to the “true” value.
Second, in studies on stable preterm infants, some devices
with sensors intended for neonatal use have given values in
the range between 65% and 80% in reasonable agreement,
while others have not.36,39,40
Third, even devices that agree within the normal range may
deviate significantly in the hypoxic range as shown in infants
born at term.41 This is most important, since it is in the hypoxic
range that values may—or may not—lead to change in clini-
cal care.
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4.4 What Is to Be Done?
Randomized clinical trials with brain injury, neurodevelopmen-
tal impairment, or mortality as the outcome will depend on a
good guess on an appropriate hypoxic threshold. The threshold
is defined by combining what is known about the pathophysi-
ology with a calibration of the device(s) used in the trial in the
hypoxic range.
In the SafeBoosC-II trial,10 the hypoxic threshold was set at
55% using two different devices that were found to give reason-
ably similar baseline values and hypoxic responses to arterial
occlusion in the adult forearm—INVOS with the adult sensor
and NIRO 200NX.42 Ideally, any cerebral oximeter that is
used in randomized trials to test clinical benefit is compared
to one of these devices and a hypoxic threshold equivalent to
55% is chosen.
For such comparison, a blood–lipid-yeast phantom may be
used in which scatter, hemoglobin concentration, and oxygena-
tion can be varied. Such a phantom is able to detect difference in
calibration between devices with good precision43 and this
data can be combined with data from infants. The goal is to
reduce the uncertainty as regards the calibration of the hypoxic
threshold to less than 5%.
The ultimate goal is a trial with large-scale application of
cerebral oximetry in the intensive care of preterm infants.
The sensors therefore also need to be simple to apply, robust
to the turmoil of intensive care, and affordable to hospitals
around the world.
5 Conclusion
Routine clinical application of cerebral oximetry is in sight, but
there are a number of issues to be solved. Large-scale clinical
trials with patient relevant outcomes, better definition of
hypoxic thresholds, and calibration of devices approved for
clinical use. These issues can be addressed in parallel.
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